SILVER SPRING, Md., March 27, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that the new television advertising campaign featuring Clotamin® will initially be aired nationwide on select cable stations including CNN, Headline News, MSNBC, Lifetime, Discovery, and others. This will be the first national television marketing campaign undertaken to raise brand awareness of Clotamin.
"Getting national exposure is critical to building customer awareness and growing sales," stated Mackie A. Barch, CEO of Sunpeaks. "The new Clotamin national advertising campaign is designed to push the brand into new markets. We couldn't be more excited for our many shareholders, customers, and potential customers."
The first Clotamin television spot has been created by Steve Procko Productions, a full service production company specializing in television commercials, infomercials, direct-response commercials, and corporate videos. The commercial is expected to premiere on select cable stations throughout the United States starting on April 2, 2012. This commercial was paid for by the Company as part of its national Clotamin marketing budget. For a sneak preview of the commercial, please visit the Sunpeaks Ventures website at www.sunpeaksventures.com/tvspots.html
Clotamin® is the world's first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin® or other anticoagulants (blood thinners).
About Sunpeaks Ventures, Inc.
Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.
For additional information, please visit www.sunpeaksventures.com.
Contact: Financial Insights 888-248-8491 or [email protected]
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Sunpeaks Ventures, Inc.